DocumentRX-7369
Issued
Read2 min

Ichnos Glenmark Files FDA IND for Pentaspecific Solid Tumour Drug ISB 2301

IGI has submitted a US IND for ISB 2301, a first-in-class pentaspecific built on the BEAT platform, with a Phase I solid tumour trial planned for 2027 pending FDA clearance.

TAG C-8816 · 483 words on the filing

Ichnos Glenmark files US FDA application for solid tumour drug ISB 2301 - Business Standard
Ichnos Glenmark files US FDA application for solid tumour drug ISB 2301 - Business Standardjarmoluk / pixabay

Summary of findings

  • IGI submitted a US FDA IND application for ISB 2301, its solid tumour candidate, reported Nov 17, 2026.
  • ISB 2301 is a first-in-class pentaspecific molecule targeting three tumour-associated antigens and activating T cells and NK cells.
  • Phase I in advanced solid tumours is planned for 2027, subject to regulatory clearance.
  • The candidate comes from IGI's proprietary BEAT multispecific platform.
  • IGI's pipeline also includes ISB 2001, a trispecific T-cell engager in Phase I for relapsed/refractory multiple myeloma.

Ichnos Glenmark Innovation (IGI) has filed an investigational new drug (IND) application with the US FDA for ISB 2301, a first-in-class pentaspecific oncology candidate, with a Phase I trial in solid tumours planned for 2027. The joint venture between Glenmark Pharmaceuticals and Ichnos Sciences confirmed the submission on November 17, 2026.

The filing moves IGI's multispecific oncology pipeline into clinical territory it has not occupied before: solid tumours. Until now, its lead clinical asset has targeted blood cancer.

What is ISB 2301?

ISB 2301 combines five binding specificities in a single molecule, built on IGI's proprietary BEAT multispecific platform. Three of those specificities recognise tumour-associated antigens. The other two activate T cells and natural killer (NK) cells through complementary mechanisms.

According to the company, the design is meant to confront two standing problems in solid tumour therapy at once — tumour heterogeneity and the tumour's ability to suppress immune responses. Targeting three antigens rather than one is the hedge against diversity; engaging two immune cell types is the hedge against suppression.

IGI says the molecule is engineered to trigger antibody-dependent cellular cytotoxicity (ADCC), inhibit immune checkpoints and induce a sustained type 1 immune response to strengthen anti-tumour activity. Those are design claims, not clinical data. What the company does point to is preclinical work: ISB 2301 showed favourable pharmacokinetic and tolerability profiles in non-human primates, which IGI says supports the proposed clinical evaluation.

What does the trial plan look like?

The planned Phase I study will assess safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumour activity in patients with advanced solid tumours. First dosing is slated for 2027, subject to regulatory clearance.

"Submission of the IND for ISB 2301 marks an important milestone in advancing IGI's multispecific oncology pipeline into clinical development," said Lida Pacaud, president and chief executive officer of IGI.

Note the gap in the announcement. No named tumour types, no dose-escalation design, no trial site count and no patient enrolment targets were disclosed. A 2027 start also means a long runway before first human data — a schedule worth watching for slippage.

How does it fit the wider pipeline?

The submission extends IGI's programme beyond haematological malignancies. Its other clinical candidate, ISB 2001, is a trispecific T-cell engager targeting CD38, BCMA and CD3 for multiple myeloma. That candidate has shown anti-tumour activity and a favourable safety profile in an ongoing Phase I study in heavily pre-treated relapsed or refractory multiple myeloma patients.

Solid tumours are a harder test. The company itself concedes that overcoming tumour heterogeneity and immune suppression in this segment "remains a challenge" — a rare admission in an announcement otherwise built on first-in-class framing. ISB 2301's multi-antigen, dual-cell-engagement design is IGI's answer; whether it survives first contact with patients will not be known until the 2027 trial reads out.

via FDA industry wire (Google News) (Source)

Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

18 articles

Linked filings

  1. V-7932
  2. C-4460
  3. E-3628
  4. V-5532
  5. K-8919

« Previous filingNext filing »